Pennant (PNTG)
Market Price (9/6/2026): $37.93 | Market Cap: $1.3 BilSector: Health Care | Industry: Health Care Facilities
Pennant (PNTG)
Market Price (9/6/2026): $37.93Market Cap: $1.3 BilSector: Health CareIndustry: Health Care Facilities
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 38% Low stock price volatilityVol 12M is 37% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Telehealth Platforms, Show more. | Weak multi-year price returns2Y Excs Rtn is -26% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 21x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 25x, P/EPrice/Earnings or Price/(Net Income) is 41x Key risksPNTG key risks include [1] an inability to attract and retain the key local leadership essential to its decentralized operating model. |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 38% |
| Low stock price volatilityVol 12M is 37% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Telehealth Platforms, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -26% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 21x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 25x, P/EPrice/Earnings or Price/(Net Income) is 41x |
| Key risksPNTG key risks include [1] an inability to attract and retain the key local leadership essential to its decentralized operating model. |
Qualitative Assessment
AI Analysis | Feedback
Pennant (PNTG) stock has gained about 10% since 5/31/2026 because of the following key factors:
1. Exceptional Fiscal Q2 2026 Performance. Pennant (PNTG) reported robust financial results for its fiscal second quarter ended June 30, 2026, significantly exceeding analyst expectations. The company announced adjusted diluted earnings per share (EPS) of $0.36, surpassing the consensus estimate of $0.3366 by 6.95%. Total revenue for the quarter reached $298.0 million, representing a substantial 35.8% year-over-year increase and beating analyst projections of $288.71 million. This strong top-line growth was supported by a 48.2% rise in adjusted EBITDA to $24.3 million.
2. Increased Full-Year 2026 Financial Guidance. Following its strong second-quarter performance, Pennant raised its full-year 2026 financial outlook, signaling management's confidence in continued operational strength. The company now anticipates full-year revenue to be between $1.17 billion and $1.19 billion and adjusted diluted EPS in the range of $1.34 to $1.41. The updated guidance also projects adjusted EBITDA to be between $94.4 million and $98.0 million for the full year.
Show more
Pennant (PNTG) stock has gained about 10% since 5/31/2026 because of the following key factors:
1. Exceptional Fiscal Q2 2026 Performance. Pennant (PNTG) reported robust financial results for its fiscal second quarter ended June 30, 2026, significantly exceeding analyst expectations. The company announced adjusted diluted earnings per share (EPS) of $0.36, surpassing the consensus estimate of $0.3366 by 6.95%. Total revenue for the quarter reached $298.0 million, representing a substantial 35.8% year-over-year increase and beating analyst projections of $288.71 million. This strong top-line growth was supported by a 48.2% rise in adjusted EBITDA to $24.3 million.
2. Increased Full-Year 2026 Financial Guidance. Following its strong second-quarter performance, Pennant raised its full-year 2026 financial outlook, signaling management's confidence in continued operational strength. The company now anticipates full-year revenue to be between $1.17 billion and $1.19 billion and adjusted diluted EPS in the range of $1.34 to $1.41. The updated guidance also projects adjusted EBITDA to be between $94.4 million and $98.0 million for the full year.
3. Strategic Acquisitions and Segment Growth. Pennant continued its strategic expansion through acquisitions, contributing to significant growth in its core segments. The company completed a sizable expansion of home health and hospice operations in the Southeast and acquired River Centre Assisted Living in Tucson, Arizona. Additionally, Pennant closed a $146.5 million acquisition of hospice and home health locations from former Amedisys and UnitedHealth Group by August 31, 2026. These acquisitions bolstered the home health and hospice segment, which saw revenue increase by 43.2%, and contributed to the 12.6% growth in senior living revenue during fiscal Q2 2026.
4. Favorable Analyst Revisions and Price Target Hikes. Analyst sentiment toward PNTG turned increasingly bullish during the period, with several firms upgrading ratings and raising price targets. Royal Bank of Canada increased its price target from $42.00 to $44.00 on August 20, 2026, maintaining an "outperform" rating. Wells Fargo & Company raised its price target from $45.00 to $46.00 on August 11, 2026, reiterating an "overweight" rating. Furthermore, Truist Financial lifted its price objective from $42.00 to $48.00 on July 14, 2026. These revisions reflect growing analyst confidence in Pennant's growth trajectory and operational execution.
Show less
Stock Movement Drivers
Fundamental Drivers
The 10.9% change in PNTG stock from 5/31/2026 to 9/5/2026 was primarily driven by a 7.7% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 5312026 | 9052026 | Change |
|---|---|---|---|
| Stock Price ($) | 34.25 | 38.00 | 10.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,023 | 1,102 | 7.7% |
| Net Income Margin (%) | 3.0% | 2.9% | -1.0% |
| P/E Multiple | 39.2 | 41.0 | 4.4% |
| Shares Outstanding (Mil) | 35 | 35 | -0.3% |
| Cumulative Contribution | 10.9% |
Market Drivers
5/31/2026 to 9/5/2026| Return | Correlation | |
|---|---|---|
| PNTG | 10.9% | |
| Market (SPY) | 1.8% | -9.7% |
| Sector (XLV) | 14.7% | 30.1% |
Fundamental Drivers
The 12.7% change in PNTG stock from 2/28/2026 to 9/5/2026 was primarily driven by a 16.3% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 2282026 | 9052026 | Change |
|---|---|---|---|
| Stock Price ($) | 33.71 | 38.00 | 12.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 948 | 1,102 | 16.3% |
| Net Income Margin (%) | 3.1% | 2.9% | -6.0% |
| P/E Multiple | 39.5 | 41.0 | 3.7% |
| Shares Outstanding (Mil) | 35 | 35 | -0.5% |
| Cumulative Contribution | 12.7% |
Market Drivers
2/28/2026 to 9/5/2026| Return | Correlation | |
|---|---|---|
| PNTG | 12.7% | |
| Market (SPY) | 12.6% | 12.5% |
| Sector (XLV) | 7.5% | 32.3% |
Fundamental Drivers
The 58.3% change in PNTG stock from 8/31/2025 to 9/5/2026 was primarily driven by a 37.9% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 8312025 | 9052026 | Change |
|---|---|---|---|
| Stock Price ($) | 24.01 | 38.00 | 58.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 799 | 1,102 | 37.9% |
| Net Income Margin (%) | 3.4% | 2.9% | -12.6% |
| P/E Multiple | 30.9 | 41.0 | 32.5% |
| Shares Outstanding (Mil) | 35 | 35 | -0.9% |
| Cumulative Contribution | 58.3% |
Market Drivers
8/31/2025 to 9/5/2026| Return | Correlation | |
|---|---|---|
| PNTG | 58.3% | |
| Market (SPY) | 20.4% | 11.8% |
| Sector (XLV) | 26.4% | 32.9% |
Fundamental Drivers
The 217.2% change in PNTG stock from 8/31/2023 to 9/5/2026 was primarily driven by a 119.6% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 8312023 | 9052026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.98 | 38.00 | 217.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 502 | 1,102 | 119.6% |
| Net Income Margin (%) | 2.6% | 2.9% | 13.6% |
| P/E Multiple | 27.6 | 41.0 | 48.6% |
| Shares Outstanding (Mil) | 30 | 35 | -14.4% |
| Cumulative Contribution | 217.2% |
Market Drivers
8/31/2023 to 9/5/2026| Return | Correlation | |
|---|---|---|
| PNTG | 217.2% | |
| Market (SPY) | 77.1% | 28.8% |
| Sector (XLV) | 34.7% | 29.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| PNTG Return | -60% | -52% | 27% | 91% | 6% | 37% | -34% |
| Peers Return | 3% | -8% | 35% | 8% | 28% | 11% | 96% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 106% |
Monthly Win Rates [3] | |||||||
| PNTG Win Rate | 17% | 50% | 50% | 67% | 67% | 67% | |
| Peers Win Rate | 50% | 48% | 60% | 56% | 58% | 47% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 56% | |
Max Drawdowns [4] | |||||||
| PNTG Max Drawdown | -72% | -62% | -32% | -29% | -27% | -18% | |
| Peers Max Drawdown | -36% | -33% | -22% | -21% | -26% | -27% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ENSG, ADUS, BKD, CHE.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/4/2026 (YTD)
How Low Can It Go
| Event | PNTG | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -17.7% | -18.8% |
| % Gain to Breakeven | 21.5% | 23.1% |
| Time to Breakeven | 61 days | 79 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -10.5% | -6.7% |
| % Gain to Breakeven | 11.8% | 7.1% |
| Time to Breakeven | 7 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -61.6% | -24.5% |
| % Gain to Breakeven | 160.1% | 32.4% |
| Time to Breakeven | 594 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -67.8% | -33.7% |
| % Gain to Breakeven | 210.9% | 50.9% |
| Time to Breakeven | 147 days | 140 days |
In The Past
Pennant's stock fell -17.7% during the 2025 US Tariff Shock. Such a loss loss requires a 21.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | PNTG | S&P 500 |
|---|---|---|
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -61.6% | -24.5% |
| % Gain to Breakeven | 160.1% | 32.4% |
| Time to Breakeven | 594 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -67.8% | -33.7% |
| % Gain to Breakeven | 210.9% | 50.9% |
| Time to Breakeven | 147 days | 140 days |
In The Past
Pennant's stock fell -17.7% during the 2025 US Tariff Shock. Such a loss loss requires a 21.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Pennant (PNTG)
The Pennant Group, Inc. (PNTG) is a healthcare services company that provides a range of care options in the United States, primarily catering to seniors and individuals requiring specialized support. The company operates through two distinct but complementary segments: Home Health and Hospice Services, and Senior Living Services.
In its Home Health and Hospice Services segment, Pennant offers comprehensive care delivered directly to patients' homes. This includes clinical services such as skilled nursing, various forms of therapy (speech, occupational, and physical), medical social work, and home health aide assistance for individuals recovering from illness or injury. For terminally ill patients and their families, the company provides hospice services that focus on clinical care, education, and counseling to address their physical, spiritual, and psychosocial needs.
Pennant's Senior Living Services segment provides residential accommodations and support for elderly individuals. These services include activities, meals, housekeeping, and assistance with daily living activities for seniors, whether they are largely independent or require some level of support. The company serves these diverse populations across 15 U.S. states, operating numerous home health and hospice agencies alongside senior living communities.
AI Analysis | Feedback
Pennant is like a regional operator that combines the senior living facilities of **Brookdale Senior Living** with the home health and hospice services of **Amedisys**.
Think of Pennant as offering a comprehensive range of senior care, from residential communities (similar to **Brookdale Senior Living**) to in-home medical and hospice support (akin to **LHC Group**).
AI Analysis | Feedback
- Home Health Services: Provides clinical services such as nursing, therapy, and medical social work for patients in their homes.
- Hospice Services: Offers clinical care, education, and counseling for terminally ill patients and their families, addressing physical, spiritual, and psychosocial needs.
- Senior Living Services: Delivers residential accommodations, activities, meals, housekeeping, and daily living assistance for independent or support-requiring seniors.
AI Analysis | Feedback
The Pennant Group, Inc. (PNTG) primarily sells its healthcare and senior living services directly to individuals.
Its customer base can be categorized as follows:
- Home Health Patients: Individuals who require various clinical services at home, including nursing, speech, occupational and physical therapy, medical social work, and home health aide services.
- Hospice Patients and their Families: Terminally ill patients and their families seeking clinical care, education, and counseling services to address their physical, spiritual, and psychosocial needs.
- Seniors in Senior Living Communities: Seniors who are independent or require some level of support with daily living, utilizing residential accommodations, activities, meals, housekeeping, and assistance with activities of daily living.
AI Analysis | Feedback
AI Analysis | Feedback
Brent J. Guerisoli, Chief Executive Officer and Chairman of the Board
Brent J. Guerisoli was appointed Chief Executive Officer of The Pennant Group, Inc. effective August 1, 2022, and became Chairman of the Board on January 1, 2025. He previously served as President of the Company from January 2021 until his appointment as CEO. Prior to that, he was President of Cornerstone Healthcare, Pennant's home health and hospice segment, where he led transformational growth, strong financial performance, and enhanced clinical excellence. Mr. Guerisoli joined the company in 2012 and has made significant contributions to the financial, clinical, and cultural achievements of Cornerstone, playing a key role in leadership recruiting and training. Throughout his tenure, he has developed numerous leaders and directed the organization's growth efforts across several states. Before joining Pennant, Mr. Guerisoli completed an executive training program and served as a business manager at AT&T.
Lynette Walbom, Chief Financial Officer
Lynette Walbom was appointed Chief Financial Officer of The Pennant Group, Inc. on May 22, 2023. Prior to joining Pennant, Ms. Walbom served as Vice President of Financial Reporting and Tax for Raising Cane's Restaurants, LLC, a national restaurant chain that more than doubled in size during her time there. At Raising Cane's, her responsibilities included financial reporting, acquisitions, tax, accounting systems, and equity management. Before her role at Raising Cane's, Ms. Walbom was the Chief Financial Officer of a family office with investments across several industries, including financial services, computer services, real estate development, and franchising. She began her 23-year career in accounting as a public company auditor at Deloitte. She was introduced to Pennant by a board member with whom she had worked for approximately 13 years in his family office.
John J. Gochnour, President and Chief Operating Officer
John J. Gochnour was appointed Chief Operating Officer of Pennant upon its formation in 2019 and subsequently became President of Pennant on August 1, 2022. Before the formation of Pennant, Mr. Gochnour served as Executive Vice President and General Counsel of Cornerstone starting in January 2013. In his current role, he oversees the operational execution across the company's two primary segments and is responsible for supporting field operations and the ongoing development of service center resources.
Kirk S. Cheney, Executive Vice President, General Counsel and Corporate Secretary
Kirk S. Cheney serves as the Company's Executive Vice President, General Counsel, and Corporate Secretary. In this capacity, Mr. Cheney is responsible for overseeing acquisitions, government relations, and the legal, regulatory, and risk management functions for the company. He also leads Pennant's Service Center.
AI Analysis | Feedback
-
Regulatory and Reimbursement Changes: Pennant's operations are highly susceptible to changes in government regulations and reimbursement policies, especially those related to Medicare, which constitutes a significant portion of the company's revenue. Adverse adjustments to Medicare reimbursement rates or policies could directly impact the company's financial stability and profitability. For example, a recent proposal by the Centers for Medicare and Medicaid Services (CMS) to raise Medicare Advantage payments by less than anticipated caused a sector-wide downturn, affecting PNTG's shares.
-
Staffing Shortages and Rising Labor Costs: Both the home health/hospice and senior living industries are labor-intensive, making them vulnerable to staffing challenges, labor shortages, and increasing wage costs. The company's ability to attract and retain qualified clinical and caregiving staff is crucial for operational efficiency and service quality. High employee turnover, competition for skilled workers, and the potential for increased costs associated with wages and benefits could strain profitability and hinder consistent service delivery.
-
Integration Risks from Acquisitions and High Debt Levels: Pennant's growth strategy often involves acquisitions, which introduce integration risks. The process of integrating newly acquired locations can lead to operational disruptions, such as "initial noise" and "choppiness in early results," requiring additional support and potentially impacting financial forecasts. Furthermore, funding these acquisitions can lead to increased indebtedness. Pennant's significant debt levels, which exceed its cash on hand, combined with a high net-debt-to-EBITDA ratio, indicate overleveraging, making incremental borrowing more expensive and increasing financial risk, particularly if profitability declines or market conditions worsen.
AI Analysis | Feedback
AI Analysis | Feedback
Home Health Services: The U.S. home healthcare market size was estimated at USD 162.35 billion in 2024 and is expected to reach USD 381.40 billion by 2033.
Hospice Services: The U.S. hospice market size was estimated at USD 29.92 billion in 2024 and is projected to grow to USD 39.09 billion by 2030.
Senior Living Services: The U.S. senior living market size was exhibited at USD 923.75 billion in 2023 and is projected to reach approximately USD 1,391.23 billion by 2033.
AI Analysis | Feedback
- Strategic Acquisitions and Integration: Pennant has recently completed significant acquisitions, including Signature Healthcare at Home and over 50 locations from UnitedHealth and Amedisys, which are anticipated to be meaningful contributors to revenue in 2026 and beyond. The company is intensely focused on integrating these newly acquired assets and optimizing their performance, which is a key part of its growth strategy.
- Organic Growth in Home Health and Hospice Services: The home health and hospice segment consistently serves as a primary engine for revenue growth. This growth is fueled by increased home health admissions and a rising hospice average daily census, alongside strong same-store Medicare admissions and an increase in Medicare revenue per episode.
- Enhanced Senior Living Occupancy and Pricing: The senior living segment is expected to contribute to revenue growth through improved occupancy rates and strategic price increases. Pennant has reported an increase in both all-store and same-store occupancy, coupled with a rise in average monthly revenue per occupied room.
- Focus on Operational Excellence and Clinical Quality: Pennant's commitment to operational excellence and high clinical quality is a fundamental driver of growth. By delivering strong clinical outcomes, such as higher CMS star ratings, the company aims to be the preferred provider in its communities, attracting more patients and payors, and thereby supporting organic revenue expansion.
AI Analysis | Feedback
Share Issuance
- The number of shares issued and outstanding has generally increased over the past few years. As of December 31, 2025, there were 34,878,000 shares issued and outstanding, compared to 34,626,000 shares at December 31, 2024.
- At December 31, 2024, there were 34,670,000 shares issued and outstanding, which was an increase from 34,373,000 shares issued and outstanding at December 31, 2023.
- As of February 28, 2022, 28,529,556 shares of common stock were outstanding.
Outbound Investments
- The company made significant acquisitions, including assets from UnitedHealth Group and Amedisys, reflecting a strategy of growth through acquiring additional operations in existing and new markets.
- Investing cash outflows in 2025 significantly exceeded operating cash inflows, driven by acquisition-related growth.
Capital Expenditures
- Capital expenditures for the fourth quarter of 2025 were $3.5 million, an increase of 4.0% year-over-year.
- For the full year 2025, capital expenditures absorbed a large share of operating cash flow, totaling $12.0 million.
- Pennant Group invested $3.6 million in capital expenditures in Q4 2025, funding long-term assets and infrastructure.
Peer Outperformance in Health Care Facilities
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 7 | 14.0% | 94.3% | 127.8% | CAH 414% · MCK 351% · COR 179% |
| Managed Health Care | 8 | 32.5% | 0.9% | 3.3% | OSCR 77% · HQY 48% · ELV 16% |
| Health Care Services | 20 | 19.7% | 53.1% | -1.5% | HIMS 238% · RDNT 134% · DGX 68% |
| Health Care Facilities ← | 24 | -1.0% | 7.5% | -19.0% | THC 249% · NHC 244% · ENSG 108% |
| Health Care Equipment | 50 | -4.5% | -4.9% | -24.0% | POCI 10775% · UFPT 318% · GKOS 200% |
| Health Care Supplies | 12 | 27.9% | -14.2% | -35.5% | LNTH 272% · HAE 59% · MMSI 23% |
| Pharmaceuticals | 63 | -1.5% | 1.9% | -36.4% | LQDA 2406% · INDV 1148% · ETON 1022% |
| Life Sciences Tools & Services | 109 | 1.6% | -27.8% | -73.9% | SNWV 1688% · MEDP 203% · AXGN 178% |
| Biotechnology | 363 | 5.6% | -26.4% | -76.8% | BRTX 73900% · DNTH 1558% · CELZ 1486% |
| Health Care Technology | 20 | -24.5% | -57.0% | -78.6% | SPOK 68% · HSTM -2% · VEEV -13% |
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 118.76 |
| Mkt Cap | 2.8 |
| Rev LTM | 2,595 |
| Op Inc LTM | 148 |
| FCF LTM | 155 |
| FCF 3Y Avg | 116 |
| CFO LTM | 224 |
| CFO 3Y Avg | 191 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 15.9% |
| Rev Chg 3Y Avg | 13.9% |
| Rev Chg Q | 8.8% |
| QoQ Delta Rev Chg LTM | 2.1% |
| Op Inc Chg LTM | 27.5% |
| Op Inc Chg 3Y Avg | 23.8% |
| Op Mgn LTM | 8.5% |
| Op Mgn 3Y Avg | 8.0% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 11.0% |
| CFO/Rev 3Y Avg | 9.6% |
| FCF/Rev LTM | 4.2% |
| FCF/Rev 3Y Avg | 4.5% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Home Health and Hospice Services | 731 | 515 | 386 | 337 | 310 |
| Senior Living Services | 210 | 175 | 148 | 127 | 130 |
| All Other | 6 | 5 | 11 | 9 | 0 |
| Total | 948 | 695 | 545 | 473 | 440 |
| $ Mil | 2025 | 2024 | 2023 | 2021 | 2018 |
|---|---|---|---|---|---|
| Home Health and Hospice Services | 121 | 88 | 66 | 56 | 23 |
| Senior Living Services | 61 | 52 | 45 | 38 | 16 |
| Net income attributable to noncontrolling interest | 4 | 2 | 1 | -1 | |
| Activities associated with transitioning operations | 1 | 1 | -1 | -3 | |
| Unusual, non-recurring, or redundant charges | -0 | -1 | -3 | 0 | |
| Start-up operations | -0 | -0 | -0 | -1 | |
| Other income | -0 | -0 | -0 | 0 | |
| Transition services costs | -1 | 0 | 0 | -2 | |
| Acquisition related costs | -7 | -1 | -0 | -0 | |
| Depreciation and amortization | -9 | -6 | -5 | -5 | |
| Share-based compensation expense | -9 | -8 | -6 | -10 | |
| Rent-cost of services | -49 | -43 | -40 | -41 | |
| Unallocated corporate expenses | -60 | -44 | -32 | ||
| All Other | -26 | -19 | |||
| Total | 52 | 38 | 25 | 5 | 21 |
Price Behavior
| Market Price | $38.00 | |
| Market Cap ($ Bil) | 1.3 | |
| First Trading Date | 10/01/2019 | |
| Distance from 52W High | -9.6% | |
| 50 Days | 200 Days | |
| DMA Price | $38.99 | $33.05 |
| DMA Trend | up | up |
| Distance from DMA | -2.5% | 15.0% |
| 3M | 1YR | |
| Volatility | 29.6% | 37.2% |
| Downside Capture | -40.40 | 16.26 |
| Upside Capture | 50.47 | 64.75 |
| Correlation (SPY) | -11.3% | 12.1% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.72 | 0.18 | -0.29 | 0.32 | 0.35 | 0.72 |
| Up Beta | -1.46 | -1.05 | 0.08 | 0.62 | 0.31 | 0.61 |
| Down Beta | 1.16 | 1.00 | -0.64 | 0.09 | 0.24 | 0.49 |
| Up Capture | -103% | 35% | -9% | 29% | 53% | 114% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 9 | 21 | 36 | 67 | 136 | 395 |
| Down Capture | 60% | 63% | -54% | 25% | 22% | 93% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 12 | 21 | 28 | 59 | 113 | 346 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PNTG | |
|---|---|---|---|---|
| PNTG | 58.1% | 37.1% | 1.30 | - |
| Sector ETF (XLV) | 26.5% | 16.0% | 1.28 | 33.6% |
| Equity (SPY) | 19.7% | 12.8% | 1.13 | 12.0% |
| Gold (GLD) | 24.6% | 29.2% | 0.75 | 7.8% |
| Commodities (DBC) | 43.8% | 20.3% | 1.67 | -11.1% |
| Real Estate (VNQ) | 9.1% | 13.6% | 0.39 | 23.0% |
| Bitcoin (BTCUSD) | -28.1% | 43.8% | -0.63 | 5.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PNTG | |
|---|---|---|---|---|
| PNTG | 5.1% | 51.3% | 0.28 | - |
| Sector ETF (XLV) | 6.6% | 15.1% | 0.25 | 28.0% |
| Equity (SPY) | 12.8% | 17.2% | 0.57 | 32.7% |
| Gold (GLD) | 19.1% | 18.8% | 0.82 | 5.2% |
| Commodities (DBC) | 10.7% | 19.5% | 0.43 | 4.5% |
| Real Estate (VNQ) | 1.7% | 18.9% | -0.01 | 33.3% |
| Bitcoin (BTCUSD) | 10.2% | 52.6% | 0.38 | 16.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PNTG | |
|---|---|---|---|---|
| PNTG | 9.7% | 61.9% | 0.48 | - |
| Sector ETF (XLV) | 10.8% | 16.7% | 0.53 | 32.8% |
| Equity (SPY) | 15.3% | 17.9% | 0.72 | 39.0% |
| Gold (GLD) | 12.4% | 16.3% | 0.62 | 8.7% |
| Commodities (DBC) | 7.9% | 18.1% | 0.35 | 15.4% |
| Real Estate (VNQ) | 4.8% | 20.7% | 0.19 | 39.4% |
| Bitcoin (BTCUSD) | 63.7% | 66.2% | 1.03 | 19.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 9/6/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/5/2026 | 0.6% | -1.1% | -0.7% |
| 5/6/2026 | 9.8% | 9.4% | -2.5% |
| 2/25/2026 | -7.9% | 1.4% | -7.6% |
| 11/5/2025 | -5.6% | 0.3% | 14.5% |
| 8/6/2025 | 8.4% | 17.2% | 9.1% |
| 5/6/2025 | 3.4% | 8.7% | 10.4% |
| 2/27/2025 | -10.8% | -9.6% | -3.6% |
| 11/6/2024 | -3.4% | -1.0% | -9.7% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 15 | 13 |
| # Negative | 13 | 9 | 11 |
| Median Positive | 8.1% | 8.7% | 12.1% |
| Median Negative | -5.6% | -13.7% | -7.6% |
| Max Positive | 14.1% | 36.8% | 29.8% |
| Max Negative | -13.1% | -16.5% | -21.5% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/5/2026 | 0.6% | -1.1% | -0.7% |
| 5/6/2026 | 9.8% | 9.4% | -2.5% |
| 2/25/2026 | -7.9% | 1.4% | -7.6% |
| 11/5/2025 | -5.6% | 0.3% | 14.5% |
| 8/6/2025 | 8.4% | 17.2% | 9.1% |
| 5/6/2025 | 3.4% | 8.7% | 10.4% |
| 2/27/2025 | -10.8% | -9.6% | -3.6% |
| 11/6/2024 | -3.4% | -1.0% | -9.7% |
| 8/6/2024 | -1.9% | 7.4% | 15.8% |
| 5/6/2024 | -3.1% | 8.4% | 10.4% |
| 2/28/2024 | 10.5% | 12.0% | 16.3% |
| 11/7/2023 | 8.1% | 11.6% | 14.1% |
| 8/8/2023 | -2.1% | 5.9% | 0.3% |
| 5/4/2023 | -6.9% | -14.3% | -3.0% |
| 2/23/2023 | 10.8% | 20.6% | 8.4% |
| 11/7/2022 | -13.1% | -16.5% | -21.5% |
| 8/8/2022 | 3.2% | 8.5% | -2.8% |
| 5/9/2022 | 14.1% | 36.8% | 29.8% |
| 2/28/2022 | -7.6% | -4.2% | 12.1% |
| 11/8/2021 | 2.1% | 6.6% | -8.8% |
| 8/9/2021 | -3.0% | -13.7% | 3.0% |
| 5/6/2021 | -2.3% | -16.2% | -12.8% |
| 2/24/2021 | -9.4% | -14.8% | -17.0% |
| 11/10/2020 | 0.3% | 10.3% | 22.1% |
| SUMMARY STATS | |||
| # Positive | 11 | 15 | 13 |
| # Negative | 13 | 9 | 11 |
| Median Positive | 8.1% | 8.7% | 12.1% |
| Median Negative | -5.6% | -13.7% | -7.6% |
| Max Positive | 14.1% | 36.8% | 29.8% |
| Max Negative | -13.1% | -16.5% | -21.5% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/05/2026 | 10-Q |
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 02/26/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/06/2024 | 10-Q |
| 12/31/2023 | 02/28/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 02/23/2023 | 10-K |
| 09/30/2022 | 11/07/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/05/2026 | 10-Q |
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 02/26/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/06/2024 | 10-Q |
| 12/31/2023 | 02/28/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 02/23/2023 | 10-K |
| 09/30/2022 | 11/07/2022 | 10-Q |
| 06/30/2022 | 08/08/2022 | 10-Q |
| 03/31/2022 | 05/09/2022 | 10-Q |
| 12/31/2021 | 02/28/2022 | 10-K |
| 09/30/2021 | 11/08/2021 | 10-Q |
| 06/30/2021 | 08/09/2021 | 10-Q |
| 03/31/2021 | 05/06/2021 | 10-Q |
| 12/31/2020 | 02/24/2021 | 10-K |
| 09/30/2020 | 11/10/2020 | 10-Q |
| 06/30/2020 | 08/11/2020 | 10-Q |
| 03/31/2020 | 05/13/2020 | 10-Q |
| 12/31/2019 | 03/04/2020 | 10-K |
| 09/30/2019 | 11/12/2019 | 10-Q |
Insider Activity
Updated 8/10/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Guerisoli, Brent | Chief Executive Officer | Direct | Sell | 8102026 | 38.52 | 4,285 | 165,067 | 3,834,634 | Form |
| 2 | Steik, Jason Paul | Chief Clinical Officer | Direct | Sell | 8102026 | 38.52 | 1,394 | 53,700 | 581,913 | Form |
| 3 | Cheney, Kirk Sterling | EVP, GC and Corp Secy | Direct | Sell | 8102026 | 38.52 | 1,393 | 53,661 | 708,843 | Form |
| 4 | Guerisoli, Brent | Chief Executive Officer | Direct | Sell | 7132026 | 41.56 | 3,159 | 131,304 | 4,315,652 | Form |
| 5 | Guerisoli, Brent | Chief Executive Officer | Direct | Sell | 7082026 | 40.51 | 3,165 | 128,214 | 4,080,977 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Guerisoli, Brent | Chief Executive Officer | Direct | Sell | 8102026 | 38.52 | 4,285 | 165,067 | 3,834,634 | Form |
| 2 | Steik, Jason Paul | Chief Clinical Officer | Direct | Sell | 8102026 | 38.52 | 1,394 | 53,700 | 581,913 | Form |
| 3 | Cheney, Kirk Sterling | EVP, GC and Corp Secy | Direct | Sell | 8102026 | 38.52 | 1,393 | 53,661 | 708,843 | Form |
| 4 | Guerisoli, Brent | Chief Executive Officer | Direct | Sell | 7132026 | 41.56 | 3,159 | 131,304 | 4,315,652 | Form |
| 5 | Guerisoli, Brent | Chief Executive Officer | Direct | Sell | 7082026 | 40.51 | 3,165 | 128,214 | 4,080,977 | Form |
| 6 | Guerisoli, Brent | Chief Executive Officer | Direct | Sell | 5272026 | 35.08 | 4,508 | 158,140 | 3,348,263 | Form |
| 7 | Cheney, Kirk Sterling | EVP, GC and Corp Secy | Direct | Sell | 8072025 | 23.34 | 880 | 20,539 | 306,221 | Form |
| 8 | Guerisoli, Brent | Chief Executive Officer | Direct | Sell | 7312025 | 23.34 | 3,995 | 93,231 | 1,913,121 | Form |
Investor Activity (13F)
Updated Sep 6, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.